At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EXAS Exact Sciences
70.96
-3.70
-4.96%
High--
Low--
Vol95.96K
Open--
D1 Closing74.66
Amplitude3.50%
Mkt Cap12.23B
Tradable Cap12.12B
Total Shares172.32M
T/O6.94M
T/O Rate0.06%
Tradable Shares170.86M
P/B3.54
ROE--
EPS-5.61
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Data provider: Ningxia XSRK Technology Limited
Exact Sciences announces improved accuracy of second-generation Cologuard test
Company Profile.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.